Zacks Investment Research cut shares of NewLink Genetics Corp (NASDAQ:NLNK) from a buy rating to a hold rating in a research report released on Wednesday, November 8th.
According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “
Several other equities analysts have also issued reports on NLNK. Robert W. Baird upgraded NewLink Genetics from a neutral rating to an outperform rating and lifted their target price for the company from $8.00 to $22.00 in a research note on Friday, September 8th. ValuEngine lowered NewLink Genetics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Stifel Nicolaus lifted their target price on NewLink Genetics from $14.00 to $29.00 and gave the company a buy rating in a research note on Monday, September 11th. Bank of America Corporation started coverage on NewLink Genetics in a research note on Friday, October 13th. They issued a buy rating and a $22.00 target price on the stock. Finally, Jefferies Group LLC cut their target price on NewLink Genetics from $26.00 to $25.00 and set a buy rating on the stock in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $23.43.
In other news, major shareholder Stine Seed Farm, Inc. bought 780,487 shares of the firm’s stock in a transaction that occurred on Friday, October 6th. The stock was purchased at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the acquisition, the insider now directly owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 13.70% of the company’s stock.
A number of large investors have recently made changes to their positions in NLNK. UBS Asset Management Americas Inc. acquired a new position in NewLink Genetics in the first quarter valued at approximately $297,000. Parametric Portfolio Associates LLC acquired a new position in NewLink Genetics in the first quarter valued at approximately $555,000. Prudential Financial Inc. acquired a new position in NewLink Genetics in the first quarter valued at approximately $443,000. American International Group Inc. lifted its holdings in NewLink Genetics by 7.1% in the first quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock valued at $321,000 after acquiring an additional 880 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in NewLink Genetics by 3.0% in the first quarter. Teachers Advisors LLC now owns 207,854 shares of the biotechnology company’s stock valued at $5,009,000 after acquiring an additional 6,047 shares during the period. 46.09% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “NewLink Genetics Corp (NASDAQ:NLNK) Cut to “Hold” at Zacks Investment Research” was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/newlink-genetics-corporation-nlnk-rating-lowered-to-hold-at-zacks-investment-research/1767156.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with our FREE daily email newsletter.